Latest News for: retinopathy of prematurity

Edit

Retinopathy of Prematurity Epidemiology Forecasts, 2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

PR Newswire 08 Dec 2023
This "Retinopathy of Prematurity (Retinopathy of Prematurity) - Epidemiology - 2032" report delivers an in-depth understanding of Retinopathy of Prematurity historical and forecasted epidemiology in ...
Edit

Lessons learnt from polio eradication programme can help improve�retinopathy of prematurity services in India: Lancet paper

The Hindu 25 Nov 2023
Retinopathy of prematurity is a serious condition that affects the vision of premature infants, and in severe cases, it can lead to permanent blindness if not identified and treated in time ....
Edit

WVU Eye Institute retinopathy of prematurity clinical trial results in FDA approval (West Virginia University Hospitals Inc)

Public Technologies 14 Mar 2023
... medication, has led to FDA approval for the treatment of retinopathy of prematurity (ROP) ... EYLEA is the first pharmacologic treatment for preterm infants with retinopathy of prematurity by the FDA.
Edit

EYLEA®(aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity ...

The Associated Press 08 Feb 2023
Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP) ... “Retinopathy of prematurity is a leading cause of childhood blindness worldwide.
Edit

FDA Advisory Committee Provides Guidance on EYLEA® (aflibercept) Injection as a New Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) (Regeneron Pharmaceuticals Inc)

Public Technologies 09 Jan 2023
FDA Advisory Committee Provides Guidance on EYLEA® (aflibercept) Injection as a New Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) ... infants with retinopathy of prematurity (ROP).
Edit

Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity (Bayer AG)

Public Technologies 11 Nov 2022
In Japan, Eylea®(aflibercept) intravitreal injection 40 mg/mL is approved for the treatment of preterm infants with retinopathy of prematurity (ROP) since September 2022.Retinopathy of prematurity is ...
Edit

EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review

PR Newswire 12 Oct 2022
Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants.
  • 1

Most Viewed

×